HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

John Frieda Offers Affordable, Salon-Level Hair Straightening With Frizz-Ease

This article was originally published in The Rose Sheet

Executive Summary

John Frieda Hair Care is positioning new Frizz-Ease 3-Day Straight as an effective and economical alternative to expensive professional hair-smoothing treatments.

You may also be interested in...



Van Tibolli’s The Best Targets Blowout Market With “Safe” Straightening

Van Tibolli Beauty hopes its GKHair The Best treatment will fill a void in the professional hair-smoothing market for formaldehyde-free and methylene-glycol-free systems. The Best features protein-based blend Juvexin, which helps to control frizz or straighten hair by reducing stiffness and causing hair to lose its natural curl.

Kao Works To Accommodate Value-Focused Consumers, Adjust To Costs

Steep raw material prices and changing consumer preferences challenge premium skin- and hair-care product firm Kao Corporation in the nine-month period ending Dec.31. The Tokyo-based firm saw operating income for its consumer products business fall ¥5.2 ($68.2 million) to ¥75.2 billion ($968.2 million).

CIR Formaldehyde Re-Review To Focus On Hair Smoothing Applications

At its March 3-4 meeting, the Cosmetic Ingredient Review Expert Panel will begin a re-review of formaldehyde to address its use in hair-smoothing products and take a first look at related ingredient methylene glycol.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017417

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel